Abstract OP0014 – Table 1

Gout risk by treatment assignment, stratified by baseline serum urate

PlaceboCanakinumab (all dosages)
NEventsRate (95% CI)NEventsRate (95% CI)HR (95% CI)
Gout events
SUA<6.9 mg/dl2326240.28 (0.18–0.41)4614190.11 (0.07–0.17)0.40 (0.22–0.73)
6.9–8.9 mg/dl831411.36 (1.00–1.85)1684410.65 (0.48–0.89)0.48 (0.31–0.74)
³9 mg/dl186345.94 (4.25–8.32)418362.55 (1.84–3.54)0.45 (0.28–0.72)
  • SUA, serum urate; Rate per 100 person-years; HR, hazard ratio; CI, confidence interval. Hazard ratios calculated using placebo as reference.